Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormonepositive/HER2−negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers.

Original languageEnglish
Pages (from-to)1898
Issue number8
Publication statusPublished - Apr 1 2022


  • adjuvant
  • breast cancer
  • chemotherapy
  • consensus
  • ctDNA
  • endocrine therapy
  • genomic signature
  • hormone receptors
  • risk of relapse
  • TNM

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review'. Together they form a unique fingerprint.

Cite this